Email this article 
Irritable Bowel Syndrome (IBS) Clinical Review
Abstract
Irritable bowel syndrome (IBS) is a chronic and recurrent functional gastrointestinal disorder that influences 9-23% of the population across the world. Patients with IBS are regularly referred to gastroenterology, go through different examinations, take different drugs, take time off work and have a low quality of life. The pathophysiology of IBS isn't yet totally comprehended and it seems to be multifactorial. Numerous pathogenetic factors, and not all necessarily present in every patient, can assume a significant part, discomfort or abdominal pain relieved by defecation, associated with an adjustment of stool form, is a typical clinical sign of IBS. Numerous variables, like emotional stress and eating, may intensify the manifestations. A timely diagnosis of IBS is significant with the goal that treatment which will give sufficient indicative alleviation (diarrhea, constipation, pain and bloating) can be presented. The finding of IBS isn't affirmed by a particular test or underlying irregularity. It is made utilizing rules dependent on clinical symptoms like Rome criteria, except if the symptoms are believed to be atypical. Today the Rome Criteria IV is the current gold standard for the determinations of IBS. Treatment of patients with IBS requires many approaches. A few patients react well to non-pharmacological treatment, while others likewise require pharmacological treatment. This review will give a summary of pathophysiology, symptomatic standards and therapies for IBS.
Keywords
Full Text:
PDFReferences
Sinagra, Emanuele, Claudia Romano, and Mario Cottone. "Psychopharmacological treatment and psychological interventions in irritable bowel syndrome." Gastroenterology Research and Practice 2012 (2012).
Belcaro, G., et al. "Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndrome." Eur Rev Med Pharmacol Sci 21.9 (2017): 2249-54. [3]. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015;313(9):949-58.
Soares, Rosa Leonôra Salerno. "Irritable bowel syndrome, food intolerance and non-celiac gluten sensitivity. A new clinical challenge." Arquivos de gastroenterologia 55.4 (2018): 417-422. [5]. Noddin, Laura, Michael Callahan, and Brian E. Lacy. "Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations?" Medscape General Medicine 7.3 (2005): 17.
Scalera, A., and C. Loguercio. "Focus on irritable bowel syndrome." Eur Rev Med Pharmacol Sci 16.9 (2012): 1155-71.
Saha, Lekha. "Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine." World Journal of Gastroenterology: WJG 20.22 (2014): 6759.
[8] Hoveyda, Nourieh, et al. "A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome." BMC gastroenterology 9.1 (2009): 1-11.
Canavan, Caroline, Joe West, and Timothy Card. "The epidemiology of irritable bowel syndrome." Clinical epidemiology 6 (2014): 71.
Grundmann, Oliver, and Saunjoo L. Yoon. "Irritable bowel syndrome: Epidemiology, diagnosis and treatment: An update for health‐care practitioners." Journal of gastroenterology and hepatology 25.4 (2010): 691-699.
Excellence, Care. "Developing NICE Guidelines: The Manual [Internet]." (2015).
Lovell, Rebecca M., and Alexander C. Ford. "Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis." Clinical gastroenterology and hepatology10.7 (2012): 712-721. [13]. Houghton, L. A., et al. "Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome." Gut 52.5 (2003): 663-670.
van der Veek, Patrick PJ, et al. "Testing a biobehavioral model of irritable bowel syndrome." European journal of gastroenterology & hepatology 22.4 (2010): 412-419.
Bellini, Massimo, et al. "Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy." World journal of gastroenterology: WJG 20.27 (2014): 8807.
Mohammed, Imtiyaz, et al. "Genetic influences in irritable bowel syndrome: a twin study." American Journal of Gastroenterology 100.6 (2005): 1340-1344.
Park, Moo-In, and Michael Camilleri. "Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment." Gastroenterology Clinics 34.2 (2005): 305-317. [18]. Colucci, Rocchina, et al. "Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome." PLoS One 8.2 (2013): e54831.
Chumpitazi, Bruno P., and Robert J. Shulman. "Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome." Molecular and cellular pediatrics 3.1 (2016): 1-9.
Zeevenhooven, Judith, Ilan JN Koppen, and Marc A. Benninga. "The new Rome IV criteria for functional gastrointestinal disorders in infants and toddlers." Pediatric gastroenterology, hepatology & nutrition 20.1 (2017): 1.
Posserud, Iris, Amanda Ersryd, and Magnus Simrén. "Functional findings in irritable bowel syndrome." World Journal of Gastroenterology: WJG 12.18 (2006): 2830.
Radovanovic-Dinic, Biljana, et al. "Irritable bowel syndrome-from etiopathogenesis to therapy." Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 162.1 (2018): 1-9.
De Ponti, F. "Pharmacology of serotonin: what a clinician should know." Gut 53.10 (2004): 1520-1535.
Mayer, Emeran A., and Sylvie Bradesi. "Alosetron and irritable bowel syndrome." Expert opinion on pharmacotherapy 4.11 (2003): 2089-2098.
Farzaei, Mohammad H., et al. "The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments." Journal of Neuro gastroenterology and Motility 22.4 (2016): 558.
Dorn, Spencer D., et al. "Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity." Gut 56.9 (2007): 1202-1209.
Nozu, Tsukasa, et al. "Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome." Journal of gastroenterology 41.3 (2006): 217-222. [28]. Mertz, H. "Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans." Gut 51. suppl 1 (2002): i29-i33.
Bonaz, B., et al. "Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study." The American journal of gastroenterology 97.3 (2002): 654-661.
Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012;61(9):1284-90.
Stasi, Cristina, et al. "Altered neuro-endocrine–immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model." Journal of gastroenterology 47.11 (2012): 1177-1185.
Dinan, Timothy G., et al. "Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?" Gastroenterology 130.2 (2006): 304-311. [33]. Hanevik, Kurt, et al. "Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study." Clinical Infectious Diseases59.10 (2014): 1394-1400.
Patel, Shaileshkumar R., et al. "Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome." Indian Journal of Pathology and Microbiology 60.3 (2017): 385.
Guinane, Caitriona M., and Paul D. Cotter. "Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ." Therapeutic advances in gastroenterology 6.4 (2013): 295-308.
Hyland, Niall P., Eamonn MM Quigley, and Elizabeth Brint. "Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions." World journal of gastroenterology: WJG 20.27 (2014): 8859.
Hyland, Niall P., Eamonn MM Quigley, and Elizabeth Brint. "Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions." World journal of gastroenterology: WJG 20.27 (2014): 8859.
Atkinson, W., et al. "Food elimination based on IgG antibodies in irritable bowel syndrome: a randomized controlled trial." Gut 53.10 (2004): 1459-1464.
Elli, Luca, et al. "Diagnosis of gluten related disorders: Celiac disease, wheat allergy and non-celiac gluten sensitivity." World journal of gastroenterology: WJG 21.23 (2015): 7110.
Biesiekierski, Jessica R., et al. "No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates." Gastroenterology 145.2 (2013): 320-328.
Seo, A. Young, Nayoung Kim, and Dong Hyun Oh. "Abdominal bloating: pathophysiology and treatment." Journal of neuro gastroenterology and motility 19.4 (2013): 433.
Layer, Peter, et al. "Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom." Therapeutics and Clinical Risk Management 3.1 (2007): 107. [43]. Bonavita, Vincenzo, and Roberto De Simone. "Towards a definition of comorbidity in the light of clinical complexity." Neurological Sciences 29.1 (2008): 99-102.
Gralnek, Ian M., et al. "The impact of irritable bowel syndrome on health-related quality of life." Gastroenterology119.3 (2000): 654-660.
Hungin, A. P. S., et al. "Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care–a Rome Foundation working team report." Alimentary pharmacology & therapeutics 40.10 (2014): 1133-1145.
Soubieres, Anet, et al. "Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service." Frontline gastroenterology 6.4 (2015): 246-251.
Sunderland, Rhian. "Irritable bowel syndrome in adults: symptoms, treatment and management." Nursing Standard31.26 (2017).
Drossman, D. A., et al. "Identification of sub-groups of functional gastrointestinal disorders." Gastroenterology international 3.4 (1990): 159-172.
Thompson, W. G., et al. "Functional bowel disorders and functional abdominal pain." Gut 45. suppl 2 (1999): II43-II47.
Drossman, Douglas A. "The functional gastrointestinal disorders and the Rome III process." gastroenterology130.5 (2006): 1377-1390.
Schmulson, Max J., and Douglas A. Drossman. "What is new in Rome IV." Journal of neuro gastroenterology and motility 23.2 (2017): 151.
Lacy, Brian E., et al. "Bowel disorders." Gastroenterology150.6 (2016): 1393-1407. [53] Simren, Magnus, Olafur S. Palsson, and William E. Whitehead. "Update on Rome IV criteria for colorectal disorders: implications for clinical practice." Current gastroenterology reports 19.4 (2017): 15.
Johannesson, Elisabet, et al. "Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial." American Journal of Gastroenterology106.5 (2011): 915-922.
Iovino, Paola, et al. "Bloating and functional gastro-intestinal disorders: where are we and where are we going?" World Journal of Gastroenterology: WJG 20.39 (2014): 14407. [56] Spiller R, Aziz Q, Creed F Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56(12):1770-98.
Volta, Umberto, et al. "Dietary triggers in irritable bowel syndrome: is there a role for gluten?" Journal of Neuro gastroenterology and Motility 22.4 (2016): 547.
Catassi, Carlo, et al. "Non-celiac gluten sensitivity: the new frontier of gluten related disorders." Nutrients 5.10 (2013): 3839-3853. A, Castillejo G, Ciacci C, Cristofori F, Dolinsek J, Francavilla R, Elli L, Green P, Holtmeier W, Koehler P, Koletzko S, Meinhold C, Sanders D, Schumann M, Schuppan D, Ullrich R, Vécsei A, Volta U, Zevallos V, Sapone A, Fasano A. Nonceliac gluten sensitivity: the new frontier of gluten related disorders. Nutrients 2013;5(10):3839-53.
Magge, Suma, and Anthony Lembo. "Low-FODMAP diet for treatment of irritable bowel syndrome." Gastroenterology & hepatology 8.11 (2012): 739.
Saha, Lekha. "Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine." World Journal of Gastroenterology: WJG 20.22 (2014): 6759.
Owens, Dorothy M., Daniel K. Nelson, and Nicholas J. Talley. "The irritable bowel syndrome: long-term prognosis and the physician-patient interaction." Annals of Internal Medicine 122.2 (1995): 107-112.
Drossman, Douglas A. "Diagnosing and treating patients with refractory functional gastrointestinal disorders." Annals of internal medicine 123.9 (1995): 688-697.
Saha, Lekha. "Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine." World Journal of Gastroenterology: WJG 20.22 (2014): 6759.
Hayes, Paula A., Marianne H. Fraher, and Eamonn MM Quigley. "Irritable bowel syndrome: the role of food in pathogenesis and management." Gastroenterology & hepatology 10.3 (2014): 164.
Park, M‐I., and Michael Camilleri. "Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review." Neuro gastroenterology & Motility 18.8 (2006): 595-607.
Böhmer, Clarisse JM, and Hans ARE Tuynman. "The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5-year follow-up study." European journal of gastroenterology & hepatology 13.8 (2001): 941-944. [67]. Deng, Yanyong, et al. "Lactose intolerance in adults: biological mechanism and dietary management." Nutrients7.9 (2015): 8020-8035.
Ford, Alexander C., et al. "American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation." Official journal of the American College of Gastroenterology| ACG 109 (2014): S2-S26. [69]. Bijkerk cJ, de Wit NJ, muris JW, Whorwell PJ, Knottnerus Ja, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? randomized placebo-controlled trial. BmJ 2009;339: b3154.
Vasagar, Brintha, et al. "World epidemiology of non-celiac gluten sensitivity." Minerva gastroenterologica e dietologica63.1 (2017): 5-15.
Caio, Giacomo, et al. "Pathophysiology of non-celiac gluten sensitivity: where are we now?" Minerva gastroenterologica e dietologica 63.1 (2016): 16-21.
Biesiekierski, Jessica R., et al. "Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial." American Journal of Gastroenterology 106.3 (2011): 508-514.
Vazquez–Roque, Maria I., et al. "A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function." Gastroenterology 144.5 (2013): 903-911.
Biesiekierski, Jessica R., et al. "No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates." Gastroenterology 145.2 (2013): 320-328.
Murray, Kathryn, et al. "Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI." The American journal of gastroenterology109.1 (2014): 110.
Halmos, Emma P., et al. "A diet low in FODMAPs reduces symptoms of irritable bowel syndrome." Gastroenterology146.1 (2014): 67-75.
Böhn, Lena, et al. "Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial." Gastroenterology 149.6 (2015): 1399-1407.
Falagiani, Paolo, et al. "Systemic nickel allergy syndrome (SNAS): A review." Rev Port Imunoalergologia 16.2 (2008): 135-47.
Pizzutelli, S. "Systemic nickel hypersensitivity and diet: myth or reality?" European annals of allergy and clinical immunology 43.1 (2011): 5.
Veien, N. K., and T. Menné. "Nickel contact allergy and a nickel-restricted diet." Seminars in dermatology. Vol. 9. No. 3. 1990.
Rizzi, Angela, et al. "Irritable bowel syndrome and nickel allergy: what is the role of the low nickel diet?" Journal of neuro gastroenterology and motility 23.1 (2017): 101.
Chey, William D., Jacob Kurlander, and Shanti Eswaran. "Irritable bowel syndrome: a clinical review." Jama 313.9 (2015): 949-958.
Almquist, Ellinor, Hans Törnblom, and Magnus Simren. "Practical management of irritable bowel syndrome: a clinical review." Minerva gastroenterologica e dietologica62.1 (2015): 30-48.
[84]. Slattery, S. A., et al. "Systematic review with meta‐analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea." Alimentary pharmacology & therapeutics 42.1 (2015): 3-11.
Wong, Banny S., et al. "Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea." Clinical gastroenterology and hepatology 10.9 (2012): 1009-1015. [86]. Bajor, Antal, et al. "Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS." Gut64.1 (2015): 84-92.
Spiller, Robin C. "Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome." Current opinion in pharmacology 11.1 (2011): 68-74.
Camilleri, Michael, and Guy Boeckxstaens. "Dietary and pharmacological treatment of abdominal pain in IBS." Gut66.5 (2017): 966-974.
Chang, Lin, Kenneth Tong, and Vanessa Ameen. "Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences." American Journal of Gastroenterology 105.4 (2010): 866-875.
Garsed, Klara, et al. "A randomized trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea." Gut 63.10 (2014): 1617-1625.
Matsueda, Kei, et al. "A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome." Scandinavian journal of gastroenterology 43.10 (2008): 1202-1211.
Wade, P. R., et al. "Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/µ opioid receptor antagonist." British journal of pharmacology 167.5 (2012): 1111-1125.
Pimentel, Mark, et al. "Rifaximin therapy for patients with irritable bowel syndrome without constipation." New England journal of medicine 364.1 (2011): 22-32.
Lembo, Anthony, et al. "Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome." Gastroenterology 151.6 (2016): 1113-1121. [95]. Törnblom, Hans, et al. "Colonic transit time and IBS symptoms: what's the link?" American Journal of Gastroenterology 107.5 (2012): 754-760.
Chapman, R. W., et al. "Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome." American Journal of Gastroenterology 108.9 (2013): 1508-1515.
Quigley, Eamonn MM. "Cisapride: what can we learn from the rise and fall of a prokinetic?" Journal of digestive diseases 12.3 (2011): 147-156.
Tack, Jan, et al. "Systematic review: cardiovascular safety profile of 5‐HT 4 agonists developed for gastrointestinal disorders." Alimentary pharmacology & therapeutics 35.7 (2012): 745-767.
Camilleri, Michael, et al. "A placebo-controlled trial of prucalopride for severe chronic constipation." New England Journal of Medicine 358.22 (2008): 2344-2354.
Tack, J., et al. "Effect of prucalopride on symptoms of chronic constipation." Neuro gastroenterology & Motility 26.1 (2014): 21-27.
Camilleri, M., et al. "Clinical trial: the efficacy of open‐label prucalopride treatment in patients with chronic constipation–follow‐up of patients from the pivotal studies." Alimentary pharmacology & therapeutics 32.9 (2010): 1113-1123.
Drossman, D. A., et al. "Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome–results of two randomized, placebo‐controlled studies." Alimentary pharmacology & therapeutics 29.3 (2009): 329-341.
Simrén, Magnus, and Jan Tack. "New treatments and therapeutic targets for IBS and other functional bowel disorders." Nature Reviews Gastroenterology & Hepatology15.10 (2018): 589-605.
Khanna, Reena, John K. MacDonald, and Barrett G. Levesque. "Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis." Journal of clinical gastroenterology 48.6 (2014): 505-512.
Delvaux, M., and D. Wingate. "Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results." Journal of international medical research 25.5 (1997): 225-246.
Ford, Alexander C., et al. "Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis." American Journal of Gastroenterology 109.9 (2014): 1350-1365.
Dekel, Roy, Douglas A. Drossman, and Ami D. Sperber. "The use of psychotropic drugs in irritable bowel syndrome." Expert opinion on investigational drugs 22.3 (2013): 329-339.
Salari, Pooneh, and Mohammad Abdollahi. "Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope?" World journal of gastroenterology: WJG 17.38 (2011): 4251.
Simrén, Magnus, et al. "Intestinal microbiota in functional bowel disorders: a Rome foundation report." Gut 62.1 (2013): 159-176.
Borowiec, Anna M., and Richard N. Fedorak. "The role of probiotics in management of irritable bowel syndrome." Current gastroenterology reports 9.5 (2007): 393-400.
Ford, Alexander C., et al. "Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis." American journal of gastroenterology 109.10 (2014): 1547-1561.
Astegiano, M., et al. "Treatment of irritable bowel syndrome. A case control experience." Minerva gastroenterologica e dietologica 52.4 (2006): 359-363.
Tanaka, Yukari, et al. "Biopsychosocial model of irritable bowel syndrome." Journal of neuro gastro enterology and motility 17.2 (2011): 131.
Zijdenbos, Ingeborg L., et al. "Psychological treatments for the management of irritable bowel syndrome." Cochrane Database of Systematic Reviews 1 (2009).
Hussain, Zahra, and E. M. M. Quigley. "Systematic review: complementary and alternative medicine in the irritable bowel syndrome." Alimentary pharmacology & therapeutics23.4 (2006): 465-471.
Ma, Xiao-Peng, et al. "Acupuncture-moxibustion in treating irritable bowel syndrome: how does it work?" World journal of gastroenterology: WJG 20.20 (2014): 6044.
Liu, Jian Ping, et al. "Herbal medicines for treatment of irritable bowel syndrome." Cochrane Database of Systematic Reviews 1 (2006).
DOI: http://dx.doi.org/10.52155/ijpsat.v27.1.3167
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Maged Naser, Mohamed M. Naser, Lamia H. Shehata
This work is licensed under a Creative Commons Attribution 4.0 International License.